A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 8, Pages 1786
Publisher
MDPI AG
Online
2017-08-21
DOI
10.3390/ijms18081786
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab in the treatment of non-small cell lung cancer
- (2017) Oscar Arrieta et al. Expert Opinion On Drug Safety
- Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option
- (2017) M Ashraf et al. EYE
- Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
- (2017) Su Jin Lee et al. INVESTIGATIONAL NEW DRUGS
- Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
- (2017) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of PDGFs and PDGFRs in Colorectal Cancer
- (2017) Roberta M. Manzat Saplacan et al. MEDIATORS OF INFLAMMATION
- Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface
- (2017) K A Khan et al. ONCOGENE
- Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
- (2016) Lauren CJ Baker et al. BRITISH JOURNAL OF CANCER
- A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors
- (2016) A. Dowlati et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- (2016) Lee S. Rosen et al. CLINICAL CANCER RESEARCH
- Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer
- (2016) Koji Takeda et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance
- (2016) S. Krishna Priya et al. International Journal of Clinical Oncology
- Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
- (2016) Daniel P. Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis and wound repair: when enough is enough
- (2016) Luisa A. DiPietro JOURNAL OF LEUKOCYTE BIOLOGY
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
- (2016) William D Tap et al. LANCET
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health
- (2016) Tomas A. Moreno et al. Seminars in Ophthalmology
- Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma
- (2016) Darrin Bann et al. Cancers
- The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis
- (2015) G. A. Smith et al. BIOSCIENCE REPORTS
- A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2015) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
- (2015) A. Scholz et al. EMBO Molecular Medicine
- Regulation of vascular endothelial growth factor in prostate cancer
- (2015) S. de Brot et al. ENDOCRINE-RELATED CANCER
- Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer
- (2015) John R. Mackey et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth
- (2015) P J Noy et al. ONCOGENE
- Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse
- (2015) Ji-Kan Ryu et al. Scientific Reports
- Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis
- (2015) Guangchao Cao et al. MEDICAL SCIENCE MONITOR
- Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
- (2015) Sang Hun Lee et al. Annals of Surgical Treatment and Research
- VEGF-independent angiogenic pathways induced by PDGF-C
- (2015) Oncotarget
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
- (2014) E. Gabriela Chiorean et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- The therapeutic monoclonal antibody market
- (2014) Dawn M Ecker et al. mAbs
- A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients
- (2014) Patrizia Mancuso et al. PLoS One
- Antiangiogenesis therapy: an update after the first decade
- (2014) Sandro De Falco KOREAN JOURNAL OF INTERNAL MEDICINE
- Mechanisms of resistance to anti-angiogenesis therapies
- (2013) Sandy Giuliano et al. BIOCHIMIE
- Molecular analysis of a recurrent glioblastoma treated with bevacizumab
- (2013) Takuya Furuta et al. Brain Tumor Pathology
- Targeting the PDGF signaling pathway in tumor treatment
- (2013) Carl-Henrik Heldin Cell Communication and Signaling
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- (2013) Y. Kienast et al. CLINICAL CANCER RESEARCH
- Update on bevacizumab and other angiogenesis inhibitors for brain cancer
- (2013) Mikael L Rinne et al. EXPERT OPINION ON EMERGING DRUGS
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- SILAC-Based Proteomics of Human Primary Endothelial Cell Morphogenesis Unveils Tumor Angiogenic Markers
- (2013) Sara Zanivan et al. MOLECULAR & CELLULAR PROTEOMICS
- Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro
- (2013) M K Ki et al. ONCOGENE
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Signal Transduction by Vascular Endothelial Growth Factor Receptors
- (2013) S. Koch et al. Cold Spring Harbor Perspectives in Medicine
- Platelet-derived growth factors and their receptors: Structural and functional perspectives
- (2012) Po-Han Chen et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Angiopoietins in angiogenesis
- (2012) Ernesta Fagiani et al. CANCER LETTERS
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
- (2012) Fabiola Cecchi et al. Current Signal Transduction Therapy
- The discovery of placenta growth factor and its biological activity
- (2012) Sandro De Falco EXPERIMENTAL AND MOLECULAR MEDICINE
- Bevacizumab: overview of the literature
- (2012) Maria Ignez Braghiroli et al. Expert Review of Anticancer Therapy
- MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models
- (2012) Ching Leow INTERNATIONAL JOURNAL OF ONCOLOGY
- Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
- (2012) Tanja Holopainen et al. JNCI-Journal of the National Cancer Institute
- Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review)
- (2012) GUANHUA SONG et al. ONCOLOGY REPORTS
- AAV2-mediated gene transfer of VEGF-Trap with potent suppression of primary breast tumor growth and spontaneous pulmonary metastases by long-term expression
- (2012) LIAN LU et al. ONCOLOGY REPORTS
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Tie2-Dependent Neovascularization of the Ischemic Hindlimb Is Mediated by Angiopoietin-2
- (2012) Michael Lekas et al. PLoS One
- Bevacizumab and ovarian cancer
- (2012) Agustin Garcia et al. Therapeutic Advances in Medical Oncology
- Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
- (2011) Sang Hoon Lee ARCHIVES OF PHARMACAL RESEARCH
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Bevacizumab in non-small-cell lung cancer: a review
- (2011) David Planchard Expert Review of Anticancer Therapy
- Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells
- (2011) Eswaran Devarajan et al. INTERNATIONAL JOURNAL OF CANCER
- RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt Pathway
- (2011) Feng Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs
- (2011) Arnold I. Caplan et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Identification and angiogenic role of the novel tumor endothelial marker CLEC14A
- (2011) M Mura et al. ONCOGENE
- Inhibition of Prostate Cancer Using RNA Interference-directed Knockdown of Platelet-derived Growth Factor Receptor
- (2011) Yong Hyun Park et al. UROLOGY
- Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2
- (2011) Jennifer Spratlin Current Oncology Reports
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion
- (2010) Seung-Sik Rho et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficient Inhibition of Non-Small-Cell Lung Cancer Xenograft by Systemic Delivery of Plasmid-Encoding Short-Hairpin RNA Targeting VEGF
- (2010) Yang Yang et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- VEGF-B: a thing of beauty
- (2010) Xuri Li CELL RESEARCH
- Targeting the Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
- (2010) M. R. Russell et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Ramucirumab (IMC-1121B): a novel attack on angiogenesis
- (2010) Jennifer L Spratlin et al. Future Oncology
- Platelet-derived Growth Factor-DD Targeting Arrests Pathological Angiogenesis by Modulating Glycogen Synthase Kinase-3β Phosphorylation
- (2010) Anil Kumar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation
- (2010) W. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine
- (2010) Toshikazu NAKAMURA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex
- (2010) A. Hye-Ryong Shim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of the Angiopoietins in vascular morphogenesis
- (2009) Markus Thomas et al. ANGIOGENESIS
- Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth
- (2009) Patrick Nasarre et al. CANCER RESEARCH
- Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy
- (2009) A. K. Lucio-Eterovic et al. CLINICAL CANCER RESEARCH
- Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma
- (2009) I. Helfrich et al. CLINICAL CANCER RESEARCH
- Src and FAK mediate cell-matrix adhesion-dependent activation of met during transformation of breast epithelial cells
- (2009) Angela Y. Hui et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Molecular Diversity of VEGF-A as a Regulator of Its Biological Activity
- (2009) Jeanette Woolard et al. MICROCIRCULATION
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
- (2009) Emmanuelle di Tomaso et al. PLoS One
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease
- (2008) T. Makinde et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
- Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization
- (2008) Y. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes
- (2007) Vadim Tchaikovski et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PI3K/PTEN signaling in tumorigenesis and angiogenesis
- (2007) Bing-Hua Jiang et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now